Statements

March 2021

March 31, 2021 3/31/2021 Takeda Provides Status Update on NATPARA US Recall

March 29, 2021 3/29/2021 Takeda Builds on 30-Year Partnership with the World Federation of Hemophilia with a Five-Year Product Donation to the Humanitarian Aid Program

March 4, 2021 3/4/2021 Takeda Announces Strategic Partnership to Accelerate the Development of Enzyre’s Diagnostic Technology Platform That Aims to Improve the Standard of Care for Patients with Bleeding Disorders

September 2020

September 1, 2020 9/1/2020 Update on the U.S. Development Program for the Investigational Subcutaneous Formulation of ENTYVIO® (vedolizumab) as a Maintenance Therapy in Adults with Moderate to Severe Ulcerative Colitis

June 2020

June 22, 2020 6/22/2020 Update of the Financial Impact of the European Commission’s Decision to Release Takeda from Commitment to Divest Shire’s Pipeline Compound SHP647

June 17, 2020 6/17/2020 Regarding a Warning Letter from the U.S. Food and Drug Administration

June 2019

June 5, 2019 6/5/2019 Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial

January 2019

January 3, 2019 1/3/2019 Takeda Notes Court Sanction of the Scheme of Arrangement with respect to the Acquisition of Shire plc

October 2018

October 26, 2018 10/26/2018 Takeda comments on ongoing Phase 1 review by the European Commission of the proposed acquisition of Shire plc